Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study Of Buntanetap For Early Parkinson's Disease

Date

7/19/2024 2:14:51 PM

(MENAFN- Investor Brand Network)

The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson's disease patients
Following the announcement of these positive results, the company's stock price surged by 76%
The data revealed that while 12% of Parkinson's Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements
Annovis held a webcast to go over the results in more depth, which is available for replay on the company's website

Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease and Parkinson's Disease, has released new data from its Phase III study of buntanetap for early Parkinson's Disease. The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson's Disease patients ( ).

Following the announcement of these positive results, the company's stock price surged by 76%. This remarkable increase reflects strong investor confidence in buntanetap's potential to address critical unmet needs in neurodegenerative disease treatment ( ). The trial results...

NOTE TO INVESTORS:
The latest news and updates relating to ANVS are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
...

BioMedWire is powered by
IBN

MENAFN19072024000224011066ID1108459903

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.